IceCure Medical LtdNASDAQ: ICCM

IceCure Medical Ltd  ICCM recently announced that it has received marketing authorization from the FDA for its next-generation single probe cryoablation system, XSense Cryoablation System with CryoProbes.

IceCure Medical (ICCM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Demonstrates public health importance of assessing ProSense®'s potential to offer optimal treatment that benefits women with early-stage breast cancer Patients, patient advocacy groups, doctors, and the general public will be welcome to participate and comment in the open public hearing IceCure welcomes a transparent public forum to share ICE3 study results and show how ProSense® cryoablation could potentially offer a minimally invasive alternative treatment to women diagnosed with early-stage breast cancer estimated at 65,000 in the U.S. annually ProSense® is already approved for the treatment of early-stage breast cancer in numerous European countries, as well as Brazil, India, and China  CAESAREA, Israel , June 4, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the U.S. Food and Drug Administration ("FDA") will convene a Medical Device Advisory Committee for a panel meeting (the "Advisory Panel") to obtain independent expert advice on scientific, technical, and policy matters related to ProSense® to help the FDA make a sound decision.

IceCure Medical Ltd (NASDAQ:ICCM ) Q1 2024 Earnings Conference Call May 28, 2024 11:00 AM ET Company Participants Michael Polyviou - Investor Relations Eyal Shamir - Chief Executive Officer Tlalit Bussi Tel-Tzure - VP, Business Development & Global Marketing Ronen Tsimerman - Chief Financial Officer & Chief Operating Officer Conference Call Participants Kemp Dolliver - Brookline Capital Markets Anthony Vendetti - Maxim Group Ben Haynor - Lake Street Capital Markets Yi Chen - H.C. Wainwright Operator Good morning, and thank you for standing by.

30% sales growth reflects continued adoption of ProSense® in the U.S. and other global markets Major milestones achieved: - Completion of landmark ICE3 trial for breast cancer - Positive final ICE3 trial data Awaiting FDA Decision  Independent studies performed globally continue to demonstrate ProSense®'s efficacy and safety across numerous indications Conference call to be held today at 11:00 am Eastern Time CAESAREA, Israel , May 28, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today reported financial results as of and for the three months ended March 31, 2024.

IceCure Medical has provided the FDA with final ICE data and various sub-analyses in their application for marketing authorization to treat early-stage breast cancer.

IceCure Medical Ltd. (NASDAQ:ICCM ) Q4 2023 Earnings Conference Call April 3, 2024 10:00 AM ET Company Participants Michael Polyviou - EVC Group, Investor Relations Eyal Shamir - Chief Executive Officer Shad Wood - VP of Sales, North American Tlalit Bussi Tel-Tzure - VP of Business Development and Global Marketing Ronen Tsimerman - Chief Financial Officer and Chief Operating Officer Conference Call Participants Kemp Dolliver - Brookline Capital Markets Yi Che - H.C.

I've long thought it to be worth diving into the world of medical device stocks. The problem is, there are a myriad of options to choose from, with many companies trading in the small- or micro-cap category.

IceCure Medical Ltd. (ICCM) came out with a quarterly loss of $0.09 per share in line with the Zacks Consensus Estimate.